2.13
0.05 (2.40%)
| Penutupan Terdahulu | 2.08 |
| Buka | 2.11 |
| Jumlah Dagangan | 8,359,978 |
| Purata Dagangan (3B) | 9,549,770 |
| Modal Pasaran | 2,097,975,936 |
| Harga / Jualan (P/S) | 22.76 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 10 Nov 2025 |
| Margin Operasi (TTM) | -390.08% |
| EPS Cair (TTM) | -0.570 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 41,192.50% |
| Nisbah Semasa (MRQ) | 2.22 |
| Aliran Tunai Operasi (OCF TTM) | -370.16 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -251.77 M |
| Pulangan Atas Aset (ROA TTM) | -55.62% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Bercampur |
| Biotechnology (Global) | Bercampur | Bercampur | |
| Stok | ImmunityBio, Inc. | Menaik | Menurun |
AISkor Stockmoo
| Konsensus Penganalisis | 5.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | 0.5 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | 2.0 |
| Purata | 1.88 |
|
ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: United states and Europe. Key revenue is generated from Europe. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Growth |
| % Dimiliki oleh Orang Dalam | 74.11% |
| % Dimiliki oleh Institusi | 9.33% |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 24.00 (D. Boral Capital, 1,026.76%) | Beli |
| Median | 16.00 (651.17%) | |
| Rendah | 8.00 (HC Wainwright & Co., 275.59%) | Beli |
| Purata | 16.00 (651.17%) | |
| Jumlah | 2 Beli | |
| Harga Purata @ Panggilan | 2.29 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| D. Boral Capital | 13 Nov 2025 | 24.00 (1,026.76%) | Beli | 2.00 |
| 05 Nov 2025 | 24.00 (1,026.76%) | Beli | 2.15 | |
| HC Wainwright & Co. | 10 Sep 2025 | 8.00 (275.59%) | Beli | 2.57 |
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |